After years of calling obesity drug stocks overhyped, a top analyst now sees Novo Nordisk as a big opportunity.

The pharmacy, called NovoCare, will allow patients to pay $499 in cash per month for the blockbuster weight loss drug.

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for ... Once called ‘a symbol of failure,’ Lehigh ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

Novo Nordisk and Gensaic have entered into a partnership worth up to $354m to develop new therapies for cardiometabolic ...

Novo Nordisk on Wednesday said it will offer its ... before insurance and other rebates is almost $1,350 per month. The site can also ship Wegovy prescriptions directly to patients' homes through ...

Novo Nordisk (NVO) is not concerned by the ongoing ... REUTERS / Reuters Lilly recently built out a new manufacturing site in North Carolina, dedicated to producing GLP-1 injectable pens.